Abstract
Quadruplet (QUAD) induction and autologous stem cell transplantation (ASCT) leads to high rates of measurable residual disease (MRD) negativity with improved outcomes in multiple myeloma (MM). The t(11;14) confers unique biology and different kinetics of treatment response. We analyzed MRD trajectories of patients treated with QUAD/ASCT and MRD-adapted post-ASCT management. Of the 302 patients assessed, 47 (16%) had t(11;14)+ MM. Median follow-up was 45.8 months. MRD negativity at <10−5 level (MRD <10−5) for t(11;14)+ vs t(11;14)− MM was 9% vs 31%, 36% vs 59%, and 53% vs 75% after induction, after ASCT, and any time on treatment, respectively. The rates of sustained MRD negativity <10−5 (S-MRD <10−5) were 38% vs 46%. Median time to MRD <10−5 was 13.6 vs 7.7 months for t(11;14)+ vs t(11;14)− MM, respectively. Progression-free survival (PFS) was superior for patients with t(11;14)+ MM, with 4-year PFS rates of 90% vs 72%. In multivariable analysis, S-MRD <10−5 were associated with reduced risk of progression or death, with no progression seen in those with t(11;14)+ MM who achieved S-MRD <10−5. In the setting of QUAD/ASCT therapy and MRD-adapted post-ASCT management, t(11;14)+ newly diagnosed MM is associated with improved prognosis despite slow conversion to MRD negativity.

This publication has 18 references indexed in Scilit: